reason report
solid guidanc soften share gain patch
trial track
bottom line radiu tymlo sale beat consensu
compani lower tymlo revenu guidanc
tymlo held reason well
despit late headwind osteoporosi product
perform driven organ growth littl pull-forward
quarter compani revis guidanc repres declin
expect tylmo sale due neg impact
tymlo start mainli manag acknowledg
disrupt phase trial enrol broadli maintain
timelin data readout first earn
call compani new ceo commentari indic
final transact elacestr remain top prioriti
late-stag discuss on-going move forward believ
osteoporosi market remain biggest growth opportun radiu
suggest compani like pursu futur bd activ
within endocrinolog space result compani report
financi result associ commentari revis guidanc
maintain price target reiter outperform rate
radiu stock believ slow revenu growth
temporari expect elacestr transact posit
catalyst stock year
tymlo sale beat consensu miss
estim tymlo sale grew y/i declin q/
 y/i increas driven growth us anabol
market market share averag y/i impact
due favor price q/q declin driven market
contract phase patient enter medicar part
coverag gap increas support commerci deduct
new year patient plan manag indic see
signific pull-forward impact result total gaap expens
consensu estim
result radiu loss per share miss
consensu beat estim non-gaap basi
radiu loss per share
sale guidanc decreas impact radiu
decreas guidanc tymlo sale year
compar recent consensu
repres declin midpoint manag commentari
base dcf
discount rate termin growth
net debt total capit
net debt total capit balanc sheet debt
year price history/av daili volume mil
compani inform svb leerink llc research
revenu
ep exclud stock option expens amort intang
pleas refer page import disclosur price chart analyst certif
suggest radiu see neg commerci impact
particularli april declin patient start howev
expect normal busi activ second-half
year compani new guidanc includ expect slowdown
rate new patient start expect partial mitig
shift virtual promot activ at-hom administr
flexibl tymlo compani anticip net price tailwind fy
primarili due earli tymlo price increas
tymlo remain track achiev anabol leadership
tymlo averag us trx market share osteoanabol
consist tymlo lilli forteo last
year quarter exit march share tymlo
maintain market leadership new start market share
slightli end result radiu
expect tymlo us market share greater
timelin target pivot readout unchang despit
disrupt trial enrol manag acknowledg disrupt
enrol key trial commentari suggest
alreadi start see sign recoveri trial activ
may aid adopt remot trial monitor phase
wearabl tymlo patch studi radiu seen continu improv
screen failur rate due addit new bone center trial site
see temporari slowdown screen
enrol due pandem also begin
see indic site activ recoveri result manag
expect enrol complet end reiter
expect data readout phase atom studi
male osteoporosi phase enrol complet data
continu expect phase emerald studi
elacestr radiu observ similar relat impact
temporari slowdown enrol april result
expect enrol complet occur
previous target data still expect
model updat quarter pt maintain updat
radiu model quarterli trend manag guidanc
commentari tymlo estim updat reflect
neg impact less
anticip result tymlo sale estim modestli lower
unchang oper expens
lower unchang later
year non loss per share significantli reduc
modestli reduc forecast
break-even rather provid compani maintain
current expens disciplin long-term revenu earn
forecast increas base continu underli share gain
tymlo ultim patch present lower expect
oper expens maintain price target
reiter outperform rate radiu stock
price target inc rate stock outperform
radiu biopharmaceut compani uniqu concentr focu drug
address unmet need women health compani revenu today deriv
second subcutan osteoanabol introduc us osteoporosi market tymlo
abaloparatid trajectori tymlo us osteoanabol market share appear predict
base prescript data proprietari medacorp physician survey expect
tymlo obtain share forecast market share provid
peak us sale support valuat radiu stock upsid investor
come potenti introduct tymlo patch test pivot phase
studi tymlo patch would elimin burden daili needl inject open
much broader prescrib patient base believ could tripl number patient
treat tymlo radiu also develop phase asset elacestr select estrogen
receptor degrad serd late-lin metastat breast cancer partnership discuss
asset on-going price target contain signific probability-of-success adjust
two clinic program increment valu potenti come tymlo patch
month price target base dcf methodolog cash flow
termin valu forecast sale subcutan tymlo risk-
adjust sale tymlo patch elacestr assum discount rate base
compani wacc assum convert debt convert stock includ
dilut share calcul price target base current stock level
addit factor cash balanc valuat
risk view outlook valuat radiu includ major chang price
reimburs coverag unit state sc tymlo compani main product
today forecast product also subject risk better-than-expect market
share gain gener forteo unexpect competit respons forteo manufactur
launch new superior drug class osteoporosi risk radiu
includ develop regulatori disappoint tymlo patch oncolog asset
elacestr two product fail compani valuat would reduc
approxim addit whether tymlo sale match estim on-going
clinic trial success dilut financ like requir product launch
order support futur commerci oper clinic develop
sale
share count period basic/dilut
guidanc
svb leerink research compani file foa visibl alpha consensu
svb leerink research llc compani file foa visibl alpha consensu
brand
type event
event trial detail
date known
up/down
expect
anticip enrol complet phase wearabl studi
anticip enrol complet phase emerald studi
svb leerink llc equiti research compani file
million
licens revenu mileston fund
svb leerink research compani file
million
licens revenu mileston fund
sale
 total revenu
sg total revenu
svb leerink research compani file
mm
pv flow
equiti
debt
